Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical study of LY03012

Trial Profile

A phase I clinical study of LY03012

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2018

At a glance

  • Drugs LY 03012 (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Sep 2018 According to a Luye Pharma Group media release, the National Medical Products Administration (NMPA) approved the clinical trials of LY03012.
    • 26 Jun 2018 New trial record
    • 19 Jun 2018 According to a Luye Pharma Group media release, clinical applications of the extended release tablets LY03012, a China Class 1.1 new chemical drug, have been formally accepted by the China Food and Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top